Satya Das, MD, MSCI, on Research Presented at the 2021 ASCO Gastrointestinal Cancer Symposium


The expert in hematology/oncology discussed what research he is most looking forward to seeing the results of at the meeting.

In an interview with CancerNetwork®, Satya Das, MD, MSCI, assistant professor of Medicine in the department of Medicine in the division of Hematology/Oncology at Vanderbilt University Medical Center, spoke about the research he is most excited to see presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium.


I’m a basically a [gastrointestinal] oncologist and I focus on neuroendocrine tumors…and also drug development. I think the things that interest me most pertain to those 2 areas. Particularly with regards to neuroendocrine tumors, I think the role for immunotherapy and the higher-grade neuroendocrine cancers is something that’s still actively being developed. There [are] some interesting data with both [peptide receptor radionuclide therapy; PRRT] outcomes in grade 3 tumors, as well as immunotherapy outcomes.

And then I think the other focus that was quite interesting to me was the overall survival results from the POLO study [NCT02184195], which is what established olaparib [Lynparza] in [patients with] BRCA-mutant [pancreatic] cancer. And actually, though [it’s] now FDA approved, the overall survival was not met between the 2 arms. I think it raises a lot of questions of how we use targeted treatment in [pancreatic] cancer.


Golan T, Hammal P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021;39(suppl 3):378.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.